Showing results (161-170 of 171) with videos related to
Sort By:
Pageof 18
International Journal of Clinical Oncology|October 9, 2024
First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048Nobuhiko Oridate, Shunji Takahashi, Kaoru Tanaka, et al.Esophagus : Official Journal of the Japan Esophageal Society|August 12, 2024
Esophagectomy for esophageal cancer in patients with a history of total pharyngolaryngectomy: a Japanese nationwide retrospective cohort studyAkihiko Okamura, Masayuki Watanabe, Jun Okui, et al.Cancer Medicine|September 10, 2021
Severe anaphylaxis caused by intravenous anti-cancer drugsNobuyuki Horita, Etsuko Miyagi, Taichi Mizushima, et al.Frontiers in Surgery|December 1, 2022
Head and neck small-cell carcinoma: A multicenter study of 39 cases from 10 institutionsHiroshi Matsuyama, Yushi Ueki, Isaku Okamoto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2026
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck CancerMakoto Tahara, Naomi Kiyota, Takeshi Kodaira, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2022
Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled TrialNaomi Kiyota, Makoto Tahara, Junki Mizusawa, et al.Oral Oncology|August 7, 2024
Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008Hidetoshi Shimizu, Takeshi Kodaira, Naomi Kiyota, et al.The New England Journal of Medicine|June 18, 2025
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck CancerRavindra Uppaluri, Robert I Haddad, Yungan Tao, et al.Cancer|July 11, 2020
Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of JapanYuki Saito, Ryuichi Hayashi, Yoshiyuki Iida, et al.Frontiers in Immunology|August 13, 2024
Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinomaTakahiro Tsujikawa, Kazuchika Ohno, Kei-Ichi Morita, et al.Pageof 18